Multiply Labs is revolutionizing cell therapy manufacturing with automated robotic systems, inspired by the chip industry. Founded in 2016, the startup uses physical AI to automate gene-modified cell therapy production for companies like Kyverna Therapeutics and Legend Biotech. They are also developing humanoid robots for lab assistance and hygiene improvement.

Cell therapies involve modifying cells for personalized disease treatment, showing promise for cancer, genetic disorders, autoimmune diseases, and more. Multiply Labs’ robotic systems ensure hygienic, precise manufacturing within controlled environments, reducing contamination risks and improving efficiency. They utilize NVIDIA Omniverse and Isaac Sim for digital twin development and robot training in lab skills.

Bioscience companies are adopting automation and simulation to enhance cell therapy manufacturing precision, output scalability, and risk reduction. By utilizing imitation learning in NVIDIA’s Isaac Sim, robots can replicate expert tasks demonstrated in videos, capturing invaluable skills of top scientists for improved control policies and processes.

Read more at NVIDIA: Multiply Labs Is Scaling Robotics-Driven Cell Therapy Biomanufacturing Labs